A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson’s Disease

Publication date: May 09, 2025

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson’s disease (PD) patients.

Concepts Keywords
Biotechnologies Clinical
China Criteria
Killer Dose
Parkinson Efficacy
Evaluate
Ncr201
Open
Parkinson
Phase
Safety
Stem
Tolerability
Treatment
Trial

Semantics

Type Source Name
pathway KEGG Parkinson disease
disease MESH tumors
disease MESH mental disorders
disease MESH Cognitive impairment
drug DRUGBANK Dopamine
disease MESH Parkinson’s Disease

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *